Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 15/20 | 0.58 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.54 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078997 | 0.86 | IMPDH2 (0.60) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6484664 | 0.85 | IMPDH2 (0.59) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6495723 | 0.83 | IMPDH2 (0.59) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7077471 | 0.82 | IMPDH2 (0.70) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL6483319 | 0.82 | IMPDH2 (0.61) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7074949 | 0.81 | IMPDH2 (0.61) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7077631 | 0.80 | IMPDH2 (0.58) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7075192 | 0.79 | IMPDH2 (0.54) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7075706 | 0.78 | IMPDH2 (0.55) | IMPDH2IMPDH1AAK1 | |
| SCHEMBL7078405 | 0.78 | IMPDH2 (0.59) | IMPDH2IMPDH1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919335-B2 | Administering a therapeutically effective amount of a heterocyclic compound to the patient for the treatment of inosine monophosphate dehydrogenase associated disorders, such as allograft rejection | BRISTOL-MYERS SQUIBB CO. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040022-A1 | Heterocycles that are inhibitors of IMPDH enzyme | XDH, IMPDH1, IMPDH2 | IMPDH2 3/4885IMPDH1 2/4885AAK1 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.